RTP Mobile Logo
A Conversation with the Investigators: Metastatic Castration-Resistant Prostate Cancer (Webinar Audio Proceedings)
Released August 2021

Featuring perspectives from Prof Johann de Bono and Drs Emmanuel S Antonarakis and Julie N Graff. Published August 30, 2021. (Webinar Audio Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of prostate cancer.

    LEARNING OBJECTIVES

    • Apply clinical research findings in the determination of best-practice selection and sequencing of available local and systemic treatment modalities for patients with metastatic castration-resistant prostate cancer (mCRPC).
    • Describe the rationale for testing patients with progressive CRPC for BRCA1/2 or related mutations, and advise individuals found to harbor these genetic abnormalities about the FDA approvals and potential benefits of PARP inhibitors.
    • Recognize the efficacy of FDA-approved and investigational PARP inhibitors in the management of mCRPC.
    • Appraise the activity of cabazitaxel in patients with mCRPC, and identify those for whom this regimen may be appropriate.
    • Appreciate available clinical trial data and ongoing research with immune checkpoint inhibitors alone or in combination with systemic or targeted agents for mCRPC, and consider the potential roles of these strategies in clinical care.
    • Discuss the efficacy and safety of 177Lu-PSMA-617 for patients with progressive PSMA-positive mCRPC.
    • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOmCRPC21/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/ASCOmCRPC21/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOmCRPC21/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/ASCOmCRPC21.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Emmanuel S Antonarakis, MD
    Professor of Oncology and Urology
    Johns Hopkins University
    The Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland

    Consulting Agreements: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Dendreon Pharmaceuticals Inc, ESSA Pharma Inc, GlaxoSmithKline, Janssen Biotech Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Sanofi Genzyme; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Dendreon Pharmaceuticals Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Novartis, Sanofi Genzyme, Tokai Pharmaceuticals Inc; Ownership Interest (Licenser of Patent): QIAGEN.

    Johann de Bono, MBChB, MSc, PhD
    Regius Professor of Cancer Research
    The Institute of Cancer Research, University of London
    The Royal Marsden Hospital
    London, United Kingdom

    Advisory Committee, Consulting Agreements and Data and Safety Monitoring Board/Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, CellCentric, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genmab, GlaxoSmithKline, Janssen Biotech Inc, Merck Serono, Merck Sharp & Dohme Corp, Menarini Silicon Biosystems, Orion Corporation (Finland), Pfizer Inc, QIAGEN, Sanofi Genzyme, Sierra Oncology, Taiho Oncology Inc, Terumo Medical Corporation, Vertex Pharmaceuticals; Contracted Research (Institution – no personal income): Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, CellCentric, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab, GlaxoSmithKline, Janssen Biotech Inc, Merck Serono, Merck Sharp & Dohme Corp, Menarini Silicon Biosystems, Orion Corporation, Pfizer Inc, Sanofi Genzyme, Sierra Oncology, Taiho Oncology Inc, Vertex Pharmaceuticals; Ownership Interest: Inventor, with no financial interest, for patent 8,822,438.

    Julie N Graff, MD
    Associate Professor, Hematology and Medical Oncology
    OHSU Knight Cancer Institute
    Portland, Oregon

    Research Funding to Institution: Astellas, Janssen Biotech Inc, Merck, Sanofi Genzyme.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck, and Sanofi Genzyme.

    Release date: August 2021
    Expiration date: August 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to program
(WIFI is recommended for best performance):